My Stanford colleague Caswell-JIn analyzes the effect of metastatic BC therapies using the Cisnet models previously applied to mammography and adj. therapy. The Cisnet models suggest a major impact for HER2-directed therapy, with lesser benefits for ER pos and less still for TNBC